WCLC 2025 - Posters & ePosters-PT2.13.01 A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC

PT2.13.01 A Phase II Trial of Induction Camrelizumab Plus Chemotherapy Followed by Chemoradiotherapy and Consolidation in Limited-Stage SCLC

Asset Subtitle

Di Liu

Meta Tag

Speaker Di Liu

Topic Small Cell Lung Cancer and Neuroendocrine Tumors